REGULATORY

Japan OKs Coverage for Susmed Insomnia App, Shionogi ADHD Therapy App

May 15, 2026

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

Japan’s Central Social Insurance Medical Council (Chuikyo) on May 13 approved insurance coverage for digital therapeutics developed by Susmed for insomnia and by Shionogi for ADHD, with reimbursements set to begin on June 1. The reimbursement price for Susmed’s insomnia…

To read the full story

Shionogi Releases Japan’s First Therapy App for Pediatric ADHD
June 8, 2026
Susmed Wins Partial Change Approval for Insomnia App, Seeks Coverage
September 8, 2025
Japan Approves Shionogi’s Therapy App for Pediatric ADHD
February 19, 2025

REGULATORY

US Opens Probe into German Drug Pricing Policies; Could Japan Be Next?
June 24, 2026
Japan Awards Sakigake Tag to AbbVie’s Bispecific Etentamig
June 24, 2026
Japan Grants Orphan Status to Vanda, Quoin Drugs, and Lots More
June 24, 2026
Carvykti Earlier Use Up for Japan Panel Review on June 29
June 23, 2026
Kampo Industry Calls for Predictable Drug Pricing to Support Stable Supply
June 23, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

Adaptation, Diversification Key as Drug Wholesalers Face Profit Squeeze

By Tatsuya Otsuka

Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…

COLUMN

More Positions, More Candidates: A Snapshot of Movement in Japan’s Pharma Industry

By Philip Carrigan

Recent trends are creating a fascinating push-and-pull effect in the talent market. We’re seeing more positions opening up, but also a greater number of candidates available, particularly in the fields of rare diseases and oncology. This “more positions, more candidates”…